ArticleJournal of translational medicine2024

Letter: The risk-benefit balance of CRISPR-Cas screening systems in gene editing and targeted cancer therapy.

Qiang Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.